Expression of hematopoietic progenitor cell associated antigen CD34 in chronic myeloid leukemia.
The expression of progenitor cell associated antigen CD34 was investigated in cells from 28 patients with chronic myeloid leukemia (CML). The CD34 positivity varied from 0-26% in patients with chronic phases CML (n = 17); from 6-64% in patients with accelerated phase CML (n = 4); and from 27-97% in the patients with blastic crisis of CML (n = 8). The difference in CD34 positivity between chronic (mean 10.1 +/- 2.3%), accelerated (37.7 +/- 13.3%) and blastic (58.0 +/- 7.3%) phases of CML is statistically significant (p less than 0.05), however, the number of patients studied, especially in accelerated and blastic phases is very small. There was no difference in the CD34 positivity of the cells in the peripheral blood and in the bone marrow. CD34 positivity was higher in patients with chronic phase CML at diagnosis (untreated patients) than in those who were studied during treatment. The possible importance of serially studying CD34 positivity in patients with CML is discussed in the paper.
Banavali
S
S
Barrett Cancer Center, University of Cincinnati, Ohio 45267.
Silvestri
F
F
Hulette
B
B
Hurtubise
P
P
Srivastava
A
A
Civin
C I
CI
Preisler
H D
HD
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000502:physiology*; D018952:Antigens, CD34; D001752:Blast Crisis / Q000276:immunology; D001853:Bone Marrow / Q000276:immunology; D001854:Bone Marrow Cells; D005260:Female; D006412:Hematopoietic Stem Cells / Q000276:immunology*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology*; D015465:Leukemia, Myeloid, Accelerated Phase / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011379:Prognosis
D015703:Antigens, CD; D018952:Antigens, CD34